- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117076
Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome
November 8, 2021 updated by: Theresa Zesiewicz, MD
The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.
Subjects will be randomized to gabapentin (IR) or Horizant™ (ER).
Dosing will be blinded to both patient and study team members.
Once study medication dosing has been optimized, subjects will then remain on a stable dose for six weeks until study endpoint, after which subjects will be down-titrated off of study medications.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- University of South Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Outpatients with a diagnosis of primary restless leg syndrome using the International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria8.
- RLS symptoms ≥ 15 nights of the month prior to study enrollment and for ≥ 4 of 7 consecutive nights in the week prior to study enrollment (if untreated).
- Age 18 years to 80 years.
- International Restless Legs Scale (IRLS) Total severity score of ≥ 15 (moderate to severe severity). 8
- Had significant sleep disturbance on item 4 of IRLS.8
- Women of child-bearing potential must use a reliable method of contraception.
- Informed consent. Subject must be willing and able to complete all study procedures.
Exclusion Criteria:
- Any illness that in the investigator's opinion preclude participation in this study.
- Subjects with non-RLS-related sleep disorders (e.g., sleep apnea)
- Subjects with neurological diseases or movement disorders other than RLS (e.g., diabetic neuropathy, Parkinson's disease, multiple sclerosis, dyskinesias, and dystonias)
- Pregnancy or lactation.
- Concurrent participation in another clinical study.
- Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini-Mental State Examination scores less than 27).
- Legal incapacity or limited legal capacity.
- History of RLS symptom augmentation or early-morning rebound with previous dopamine-agonist treatment.
- Clinically significant abnormalities in renal function. 3,8,10
- Presence of severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease.
- Concomitant treatment with drugs known to affect sleep/wake, RLS or periodic limb movements, including antidepressants. Subjects receiving treatment for RLS at screening will be required to discontinue and wash out for a minimum of 5 half-lives.
- Body mass index greater than 34 kg/m2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: gabapentin immediate release
Gabapentin IR is the immediate release form of the medication.
Subjects randomized to gabapentin IR will be started out at a dose of 300mg per day, taken one hour before bedtime for the first week.
Daily dose will be increased by 300 mg daily every 4 days until 1200 mg of gabapentin IR is reached or until a stable, tolerated dose of gabapentin IR that relieves symptoms has been maintained for 2 weeks (IRLS scores less than 15).
Those patients who cannot tolerate gabapentin IR will be allowed to down titrate by one dose level (300 mg daily), before dropping out of the study.
|
up to 1200 mg per day
Other Names:
|
Active Comparator: gabapentin enacarbil extended release
Horizant is the extended release form of gabapentin enacarbil.
Subjects randomized to Horizant will take 600mg at 5 pm.
After four days of stable dosing of Horizant, subjects in this study group will be evaluated by phone for changes in RLS symptoms and Patient Global Impression scale to determine if a dose increase is warranted.
Subjects in this group may be titrated up to 1200 mg daily during the 2 week titration period.
|
up to 1200 mg per day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
International Restless Leg Syndrome Rating Scale (IRLS)
Time Frame: 10 weeks
|
The IRLS is a measure of severity of Restless Legs Syndrome. It includes 10 items, measured on a scale of 0-4. A score of 1-10 indicates mild severity, 11-20 indicates moderate severity, 21-30 is severe and 31-40 is very severe. Primary outcome is the difference in IRLS scores for each of the treatment regimens. from 0 to 4. |
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Restless Leg Syndrome Quality of Life Scale (RLSQoL)
Time Frame: Baseline, day 35, day 54.
|
The Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) assesses the impact of RLS on daily life, emotional well-being, social life, and work life.
|
Baseline, day 35, day 54.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medical Outcomes Study (MOS) Sleep Scale
Time Frame: Baseline, day 35, day 54
|
The MOS Sleep Scale consists of 12 individual items (4 sleep disturbance, 2 sleep adequacy, 1 quantity of sleep and optimal sleep, 3 somnolence, 1 snoring, and 1 shortness of breath) and takes 5 to 10 minutes to complete.
Question 1 is scored on a scale of 1 to 5 ( 1 = 0-15 min to more than 60 min) and Questions 2 to 12 are scored on a scale of 1 to 6 (1 = all of the time to 6 = none of the time.
The Sleep Disturbance Subscale score is derived from the scores to Questions 1, 3, 7, and 8 and ranges from 0 to 100, where higher scores indicate greater sleep disturbance.
|
Baseline, day 35, day 54
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Theresa Zesiewicz, MD, FAAN, University of South Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 1, 2016
Study Registration Dates
First Submitted
April 15, 2014
First Submitted That Met QC Criteria
April 15, 2014
First Posted (Estimate)
April 17, 2014
Study Record Updates
Last Update Posted (Actual)
November 16, 2021
Last Update Submitted That Met QC Criteria
November 8, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Dyskinesias
- Psychomotor Disorders
- Parasomnias
- Syndrome
- Psychomotor Agitation
- Restless Legs Syndrome
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Anticonvulsants
- Antimanic Agents
- Gabapentin
Other Study ID Numbers
- RLS and Gabapentin or Horizant
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Leg Syndrome
-
Makassed General HospitalCompleted
-
Yale UniversityMerz North America, Inc.CompletedRestless Leg SyndromeUnited States
-
Lake Erie Research InstituteCompletedRestless Leg SyndromeUnited States
-
TC Erciyes UniversityNot yet recruitingThe Effect of Kinesio Taping and Manual Lymph Drainage on Pregnant Women With Restless Legs SyndromePregnancy | Nursing | Restless Leg SyndromeTurkey
-
UCB PharmaCompleted
-
Nanjing Medical UniversityCompletedCesarean Section | Restless Leg SyndromeChina
-
Saint Thomas Hospital, PanamaCompleted
-
Chinese University of Hong KongCompletedObstructive Sleep Apnea Syndrome | Restless Leg SyndromeHong Kong
-
Children's Hospitals and Clinics of MinnesotaCompletedIron Deficiency | Restless Leg SyndromeUnited States
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
Clinical Trials on Gabapentin immediate release
-
Azurity PharmaceuticalsCompletedAbuse PotentialUnited States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
GlaxoSmithKlineQuotient ClinicalCompletedAutoimmune DiseasesUnited Kingdom
-
GlaxoSmithKlineQuotient SciencesCompletedAutoimmune DiseasesUnited Kingdom
-
Heptares Therapeutics LimitedQuotient ClinicalCompletedAlzheimer's DiseaseUnited Kingdom
-
PfizerCompleted
-
PfizerCompletedHealthy ParticipantsBelgium
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2 | Type 2 Diabetes MellitusUnited States
-
PfizerCompletedHealthy SubjectsUnited States
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States